Empagliflozin Is Associated with Fewer Adverse Renal Outcomes

Lower risk for progression to macroalbuminuria accounted for most of the benefit.

In a recent placebo-controlled randomized trial that involved 7000 patients with long-standing type 2 diabetes and documented cardiovascular disease, empagliflozin (Jardiance; a sodium–glucose cotransporter–2 inhibitor) lowered the incidence of myocardial infarction, stroke, and cardiovascular-related death by 1.6 percentage points during 3 years (NEJM JW Gen Med Oct 15 2015 and N Engl J Med 2015; 373:2117). Now, the researchers present renal outcomes.

The composite renal outcome of incident or worsening nephropathy occurred in significantly fewer empagliflozin patients than placebo patients (13% vs. 19%). Differences between groups (empagliflozin vs. placebo) for the four components of this composite endpoint were as follows:

Progression to …

Reviewing Author

Allan S. Brett, MD

Disclosures

Nothing to disclose

Allan S. Brett, MD

Disclosures

Nothing to disclose

Empagliflozin Is Associated with Fewer Adverse Renal Outcomes

Topics

Reviewing Author